[go: up one dir, main page]

NO970894L - Farmasöytiske preparater inneholdende et gallesalt og en buffer for ökt biotilgjengelighet av en aktiv forbindelse - Google Patents

Farmasöytiske preparater inneholdende et gallesalt og en buffer for ökt biotilgjengelighet av en aktiv forbindelse

Info

Publication number
NO970894L
NO970894L NO970894A NO970894A NO970894L NO 970894 L NO970894 L NO 970894L NO 970894 A NO970894 A NO 970894A NO 970894 A NO970894 A NO 970894A NO 970894 L NO970894 L NO 970894L
Authority
NO
Norway
Prior art keywords
buffer
active compound
pharmaceutical preparations
bile salt
preparations containing
Prior art date
Application number
NO970894A
Other languages
English (en)
Other versions
NO970894D0 (no
Inventor
Roger Randal Charles New
Original Assignee
Cortecs Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cortecs Ltd filed Critical Cortecs Ltd
Publication of NO970894D0 publication Critical patent/NO970894D0/no
Publication of NO970894L publication Critical patent/NO970894L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Preparater inneholdende et galle- salt og en buffer, slik som et karbonat- eller bikarbonatsalt som er til- passet å bufre tarmkanalen til en pH fra 7,5 til 9, med evne til å øke bio- tilgjengeligheten av et aktivt molekyl samtidig som det minker de toksiske bivirkninger, som er generelt forbundet med gallesalter.
NO970894A 1994-08-31 1997-02-27 Farmasöytiske preparater inneholdende et gallesalt og en buffer for ökt biotilgjengelighet av en aktiv forbindelse NO970894L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9417524A GB9417524D0 (en) 1994-08-31 1994-08-31 Pharmaceutical compositions
PCT/GB1995/002015 WO1996006635A1 (en) 1994-08-31 1995-08-25 Pharmaceutical compositions containing a bile salt and a buffer for increased bioavailability of an active compound

Publications (2)

Publication Number Publication Date
NO970894D0 NO970894D0 (no) 1997-02-27
NO970894L true NO970894L (no) 1997-02-27

Family

ID=10760623

Family Applications (1)

Application Number Title Priority Date Filing Date
NO970894A NO970894L (no) 1994-08-31 1997-02-27 Farmasöytiske preparater inneholdende et gallesalt og en buffer for ökt biotilgjengelighet av en aktiv forbindelse

Country Status (13)

Country Link
US (1) US5853748A (no)
EP (1) EP0769960A1 (no)
JP (1) JPH10504835A (no)
KR (1) KR970705406A (no)
AU (1) AU705123B2 (no)
CA (1) CA2198721A1 (no)
FI (1) FI970825L (no)
GB (1) GB9417524D0 (no)
IL (1) IL115097A0 (no)
NO (1) NO970894L (no)
NZ (1) NZ291863A (no)
WO (1) WO1996006635A1 (no)
ZA (1) ZA957247B (no)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU748147B2 (en) 1997-05-19 2002-05-30 Repligen Corporation Method for assisting in differential diagnosis and treatment of autistic syndromes
US6197746B1 (en) 1998-05-19 2001-03-06 Repligen Corporation Method of using secretin for treating autism
CA2294988C (en) 1997-07-01 2015-11-24 Isis Pharmaceuticals Inc. Compositions and methods for the delivery of oligonucleotides via the alimentary canal
US6221378B1 (en) 1998-02-10 2001-04-24 Generex Pharmaceuticals Incorporated Mixed micellar delivery system and method of preparation
US7070799B1 (en) * 1998-02-10 2006-07-04 Generex Pharmaceuticals, Inc. Method for administering insulin to the buccal region
US6974590B2 (en) 1998-03-27 2005-12-13 Cima Labs Inc. Sublingual buccal effervescent
US20030118645A1 (en) * 1998-04-29 2003-06-26 Pather S. Indiran Pharmaceutical compositions for rectal and vaginal administration
US20030091629A1 (en) * 1998-03-27 2003-05-15 Cima Labs Inc. Sublingual buccal effervescent
CA2329130A1 (en) * 1998-05-21 1999-11-25 Isis Pharmaceuticals Inc. Compositions and methods for non-parenteral delivery of oligonucleotides
AU764370B2 (en) * 1998-06-18 2003-08-14 George Washington University, The Methods of administering camptothecin compounds for the treatment of cancer with reduced side effects
TW570805B (en) * 1998-09-01 2004-01-11 Hoffmann La Roche Water-soluble pharmaceutical composition in an ionic complex
US6294153B1 (en) 1998-12-21 2001-09-25 Generex Pharmaceuticals, Inc. Aerosol pharmaceutical formulation for pulmonary and nasal delivery
US6761903B2 (en) 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
US6350432B1 (en) 1999-03-19 2002-02-26 Generex Pharmaceuticals Incorporated Pressurized container having an aerosolized pharmaceutical composition
US7169889B1 (en) 1999-06-19 2007-01-30 Biocon Limited Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin
US6458383B2 (en) 1999-08-17 2002-10-01 Lipocine, Inc. Pharmaceutical dosage form for oral administration of hydrophilic drugs, particularly low molecular weight heparin
GB2355009A (en) 1999-07-30 2001-04-11 Univ Glasgow Peptides conjugated to bile acids/salts
US20030235629A1 (en) 1999-11-06 2003-12-25 Janmarie Hornack Dietary supplement containing alkaline electrolyte buffers
US9357797B2 (en) 1999-11-06 2016-06-07 Janmarie Hornack Dietary supplement containing alkaline electrolyte buffers
US7060675B2 (en) 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
US6867183B2 (en) 2001-02-15 2005-03-15 Nobex Corporation Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US20030003537A1 (en) * 2001-04-30 2003-01-02 Ventana Medical Systems, Inc. Method and composition of matter for enhancing staining of microorganisms
US7713932B2 (en) 2001-06-04 2010-05-11 Biocon Limited Calcitonin drug-oligomer conjugates, and uses thereof
US6828305B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6858580B2 (en) * 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6828297B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6713452B2 (en) * 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US20030068356A1 (en) * 2001-07-10 2003-04-10 Pather S. Indiran Sequential drug delivery systems
US6770625B2 (en) 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
US7312192B2 (en) 2001-09-07 2007-12-25 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7166571B2 (en) 2001-09-07 2007-01-23 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7030082B2 (en) * 2001-09-07 2006-04-18 Nobex Corporation Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith
US7196059B2 (en) 2001-09-07 2007-03-27 Biocon Limited Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US6913903B2 (en) 2001-09-07 2005-07-05 Nobex Corporation Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
CN100450547C (zh) 2002-01-16 2009-01-14 安斯泰来制药有限公司 改善口服吸收用药物组合物
US7601688B2 (en) 2002-06-13 2009-10-13 Biocon Limited Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus
GB0217056D0 (en) * 2002-07-23 2002-08-28 Ass Octel Use
GB0308732D0 (en) * 2003-04-15 2003-05-21 Axcess Ltd Absorption enhancers
GB0308734D0 (en) * 2003-04-15 2003-05-21 Axcess Ltd Uptake of macromolecules
KR101184138B1 (ko) * 2003-12-31 2012-09-19 시마 랩스 인크. 일반적인 선형 발포성 경구 펜타닐 투약 제형 및 투여 방법
MXPA06007453A (es) 2003-12-31 2007-01-31 Cima Labs Inc Forma de dosificacion de opiaceo oral efervescente.
WO2005065317A2 (en) * 2003-12-31 2005-07-21 Cima Labs Inc. Effervescent oral fentanyl dosage form
US20070219131A1 (en) * 2004-04-15 2007-09-20 Ben-Sasson Shmuel A Compositions capable of facilitating penetration across a biological barrier
MXPA06011871A (es) * 2004-04-15 2007-10-08 Chiasma Inc Composiciones capaces de facilitar la penetracion a traves de una barrera biologica.
US7872095B2 (en) 2004-07-19 2011-01-18 Biocon Limited Insulin-oligomer conjugates, formulations and uses thereof
JP5047978B2 (ja) * 2005-10-13 2012-10-10 バイオコン・リミテッド インスリン複合体の調製のための方法
KR100700948B1 (ko) * 2006-05-25 2007-03-28 삼성전자주식회사 이동통신 시스템에서 무선 랜의 다중 채널을 이용하는데이터 전송 장치 및 방법
CN101939023B (zh) 2007-10-16 2016-08-03 百康有限公司 可经口给药的固体药物组合物及其方法
FR2925333B1 (fr) * 2007-12-19 2012-04-13 Farid Bennis Compositions pharmaceutiques renfermant au moins un principe actif proteinique protege des enzymes digestives
RU2678833C2 (ru) 2008-09-17 2019-02-04 Киазма Инк. Фармацевтические композиции и соответствующие способы доставки
GB0817969D0 (en) * 2008-10-01 2008-11-05 Axcess Ltd Pharmaceutical composition
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
US8101593B2 (en) 2009-03-03 2012-01-24 Kythera Biopharmaceuticals, Inc. Formulations of deoxycholic acid and salts thereof
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
MX363465B (es) 2011-02-18 2019-03-25 Kythera Biopharmaceuticals Inc Tratamiento de la grasa submental.
CA2952179C (en) 2014-06-27 2019-01-08 Medytox Inc. Methods and compositions of bile acids and salts for reduction of fat
US9498485B2 (en) 2014-08-28 2016-11-22 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
US20170246187A1 (en) 2014-08-28 2017-08-31 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
HUE071943T2 (hu) 2015-02-03 2025-10-28 Amryt Endo Inc Akromegália kezelése oktreotid orális alkalmazásával
WO2016205423A2 (en) 2015-06-15 2016-12-22 Lipocine Inc. Composition and method for oral delivery of androgen prodrugs
CA3078723A1 (en) 2016-11-28 2018-05-31 Nachiappan Chidambaram Oral testosterone undecanoate therapy
US12150945B2 (en) 2018-07-20 2024-11-26 Lipocine Inc. Liver disease
US11141457B1 (en) 2020-12-28 2021-10-12 Amryt Endo, Inc. Oral octreotide therapy and contraceptive methods
GB2625490A (en) * 2021-01-27 2024-06-19 D&D Pharmatech Inc Pharmaceutical composition comprising large physiologically active substance and excipient
EP4400094A4 (en) * 2021-09-07 2025-08-27 D&D Pharmatech Inc PHARMACEUTICAL COMPOSITION COMPRISING A PHYSIOLOGICALLY ACTIVE SUBSTANCE AND AN EXCIPIENT
KR102722651B1 (ko) * 2022-01-10 2024-10-29 경북대학교 산학협력단 우르소데옥시콜레이트 함유 서방성 약학 조성물
CN118662477A (zh) * 2024-05-27 2024-09-20 重庆医科大学 一种外泌体包裹的特立帕肽脂质纳米粒及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL68769A (en) * 1983-05-23 1986-02-28 Hadassah Med Org Pharmaceutical compositions containing insulin for oral administration
GB8909022D0 (en) * 1989-04-20 1989-06-07 Cortecs Ltd Pharmaceutical compositions
GB9013448D0 (en) * 1990-06-15 1990-08-08 Sandoz Ltd Pharmaceutical resorption-improved somatostatin compositions,their preparation and use
JPH04149126A (ja) * 1990-10-09 1992-05-22 Mitsubishi Kasei Corp 経粘膜投与用医薬組成物
IT1245890B (it) * 1991-04-12 1994-10-25 Alfa Wassermann Spa Formulazioni farmaceutiche per uso orale gastroresistenti contenenti acidi biliari.
DE4234537A1 (de) * 1992-10-14 1994-04-21 Hoechst Ag Zubereitung, enthaltend Insulin und polymere Gallensäure

Also Published As

Publication number Publication date
IL115097A0 (en) 1996-01-19
FI970825A0 (fi) 1997-02-27
AU705123B2 (en) 1999-05-13
MX9701455A (es) 1998-05-31
FI970825A7 (fi) 1997-02-27
NZ291863A (en) 1998-12-23
AU3351095A (en) 1996-03-22
ZA957247B (en) 1997-02-28
KR970705406A (ko) 1997-10-09
US5853748A (en) 1998-12-29
WO1996006635A1 (en) 1996-03-07
GB9417524D0 (en) 1994-10-19
NO970894D0 (no) 1997-02-27
CA2198721A1 (en) 1996-03-07
JPH10504835A (ja) 1998-05-12
EP0769960A1 (en) 1997-05-02
FI970825L (fi) 1997-02-27

Similar Documents

Publication Publication Date Title
NO970894L (no) Farmasöytiske preparater inneholdende et gallesalt og en buffer for ökt biotilgjengelighet av en aktiv forbindelse
NO996349D0 (no) Farmasoeytisk sammensetning som har antitumoraktivitet og/eller reduserte bivirkninger, inneholdende et antitumormiddel og et hydroksimsyrederivat
NO914356L (no) Mono n-substituerte 1,4,7,10-tetraazacyklododekanderivater, fremgangsmaater for fremstilling av dem og farmasoeytiskemidler som inneholder dem
BR9809468A (pt) Formulações farmacêuticas contendo voriconazol
BR9809304A (pt) "formulações de proteìna c ativada"
DK0889875T3 (da) Cycloproylalkansyrederivater
PT951474E (pt) Novos derivados da ciclosporina sua preparacao e composicoes farmaceuticas que os contem
DE69528005D1 (de) Prolineamid-Derivate
NO962841D0 (no) Anvendelse av 2-hydroksy-5-fenylazobenzosyrederivater som colon cancer kjemopreventativer og kjemoterapeutiske midler
MY133473A (en) Haterocyclic glycyl beta-alanine derivatives.
TR199701654T1 (xx) 4-Fenilaminotiyazol t�revleri.
ES2167463T3 (es) Componentes de un compuesto medicinal que comprenden derivados n-sustituidos de la o-toluidina y preparacion percutaneamente absorbible.
ATE321543T1 (de) Pharmazeutische zusammensetzungen mit hydroximsäurederivaten
EP0773022A3 (de) Pharmazeutische Zubereitung zur Behandlung akuter Rhinitiden, enthaltend Sympthomimeticum und Pantothenol und/oder Pantothensäure
ATE164848T1 (de) 4''-deoxyerythromycinderivate
DK0648779T3 (da) 11-benzaldoxim-17beta-methoxy-17alfa-methoxymethyl-estradien-derivater, fremgangsmåder til deres fremstilling og lægemidler indeholdende disse forbindelser
AU7351881A (en) Stabilization of pharmaceutical compositions containing acid addition salts of thieno-pyridine derivatives
DK72289D0 (da) Cephemcarboxylsyreestere, deres fremstilling og anvendelse
AU5879798A (en) Agents inhibiting progress of pterygium and postoperative recurrence of the same
DE69722610D1 (de) Neue Inhalationspräparate enthaltend CR 2039 (Andolast)
EP0816366A4 (en) IMIDAZOTHIAZOLE COMPOUNDS
DE69932714D1 (de) Suesstoffzusammensetzung
MX9709453A (es) Composicion farmaceutica oral de compuestos de piperidinoalcanol en forma de solucion.
DK0742716T3 (da) Farmaceutisk sammensætning til systemisk transdermal indgivelse med det aktive middel morphin-6-glucuronid
NO943008L (no) Renseblanding for galleveiene